[1]
Lazreg S,Merad Z,Nouri MT,Garout R,Derdour A,Ghroud N,Kherroubi R,Meziane M,Belkacem S,Ouhadj O,Baudouin C,Tiar M, Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. Journal francais d'ophtalmologie. 2018 Dec;
[PubMed PMID: 30477719]
[2]
Danarti R,Ariwibowo L,Radiono S,Budiyanto A, Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases. Dermatology (Basel, Switzerland). 2016;
[PubMed PMID: 27592104]
Level 3 (low-level) evidence
[3]
Cruickshank JM, The Role of Beta-Blockers in the Treatment of Hypertension. Advances in experimental medicine and biology. 2017;
[PubMed PMID: 27957711]
Level 3 (low-level) evidence
[4]
Fonarow GC, Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. Reviews in cardiovascular medicine. 2006 Winter;
[PubMed PMID: 16534490]
[6]
Sweany AE,Moncloa F,Vickers FF,Zupkis RV, Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clinical pharmacology and therapeutics. 1985 Feb;
[PubMed PMID: 3881206]
[9]
Orme M,Collins S,Dakin H,Kelly S,Loftus J, Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Current medical research and opinion. 2010 Mar;
[PubMed PMID: 20014995]
Level 3 (low-level) evidence
[10]
Onishchenko AL,Isakov IN,Kolbasko AV,Makogon SI, [Initial combination therapy for primary open-angle glaucoma]. Vestnik oftalmologii. 2019;
[PubMed PMID: 31215532]
[12]
Wiysonge CS,Bradley HA,Volmink J,Mayosi BM,Opie LH, Beta-blockers for hypertension. The Cochrane database of systematic reviews. 2017 Jan 20;
[PubMed PMID: 28107561]
Level 1 (high-level) evidence
[13]
Goldberger JJ,Bonow RO,Cuffe M,Liu L,Rosenberg Y,Shah PK,Smith SC Jr,Subačius H, Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. Journal of the American College of Cardiology. 2015 Sep 29;
[PubMed PMID: 26403339]
[14]
Sprenger T,Viana M,Tassorelli C, Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018 Apr;
[PubMed PMID: 29671241]
[15]
January CT,Wann LS,Alpert JS,Calkins H,Cigarroa JE,Cleveland JC Jr,Conti JB,Ellinor PT,Ezekowitz MD,Field ME,Murray KT,Sacco RL,Stevenson WG,Tchou PJ,Tracy CM,Yancy CW, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;
[PubMed PMID: 24682347]
Level 1 (high-level) evidence
[16]
Kiland JA,Gabelt BT,Kaufman PL, Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Experimental eye research. 2004 Mar;
[PubMed PMID: 15106944]
[17]
Watanabe K,Chiou GC, Action mechanism of timolol to lower the intraocular pressure in rabbits. Ophthalmic research. 1983;
[PubMed PMID: 6314218]
[18]
Neufeld AH, Experimental studies on the mechanism of action of timolol. Survey of ophthalmology. 1979 May-Jun;
[PubMed PMID: 223248]
Level 3 (low-level) evidence
[19]
McLaughlin CW,Peart D,Purves RD,Carré DA,Peterson-Yantorno K,Mitchell CH,Macknight AD,Civan MM, Timolol may inhibit aqueous humor secretion by cAMP-independent action on ciliary epithelial cells. American journal of physiology. Cell physiology. 2001 Sep;
[PubMed PMID: 11502564]
[21]
Darrow DH,Greene AK,Mancini AJ,Nopper AJ, Diagnosis and Management of Infantile Hemangioma. Pediatrics. 2015 Oct;
[PubMed PMID: 26416931]
[23]
López-Sendón J,Swedberg K,McMurray J,Tamargo J,Maggioni AP,Dargie H,Tendera M,Waagstein F,Kjekshus J,Lechat P,Torp-Pedersen C, Expert consensus document on beta-adrenergic receptor blockers. European heart journal. 2004 Aug;
[PubMed PMID: 15288162]
Level 3 (low-level) evidence
[24]
Nuttall SL,Toescu V,Kendall MJ, beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ (Clinical research ed.). 2000 Feb 26;
[PubMed PMID: 10688573]
[25]
Galcerá-Tomás J,Castillo-Soria FJ,Villegas-García MM,Florenciano-Sánchez R,Sánchez-Villanueva JG,de La Rosa JA,Martínez-Caballero A,Valentí-Aldeguer JA,Jara-Pérez P,Párraga-Ramírez M,López-Martínez I,Iñigo-García L,Picó-Aracil F, Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction. Circulation. 2001 Feb 13;
[PubMed PMID: 11171788]
Level 1 (high-level) evidence
[26]
Sipahi I,Tuzcu EM,Wolski KE,Nicholls SJ,Schoenhagen P,Hu B,Balog C,Shishehbor M,Magyar WA,Crowe TD,Kapadia S,Nissen SE, Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Annals of internal medicine. 2007 Jul 3;
[PubMed PMID: 17606956]
[27]
Carnagarin R,Kiuchi MG,Ho JK,Matthews VB,Schlaich MP, Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. Frontiers in neuroscience. 2018;
[PubMed PMID: 30728760]
[28]
Sackner-Bernstein JD,Mancini DM, Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA. 1995 Nov 8;
[PubMed PMID: 7474194]
[29]
Hommer A,Hubatsch DA,Cano-Parra J, Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma. Journal of ophthalmology. 2015;
[PubMed PMID: 26495134]
[30]
Negri L,Ferreras A,Iester M, Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. Journal of ophthalmology. 2019;
[PubMed PMID: 31191995]
Level 2 (mid-level) evidence
[31]
Taniguchi T,Kitazawa Y, The potential systemic effect of topically applied beta-blockers in glaucoma therapy. Current opinion in ophthalmology. 1997 Apr;
[PubMed PMID: 10168358]
Level 3 (low-level) evidence